Streetbeat News

Price Targets

HLVX

HC Wainwright & Co. analyst Matthew Caufield has initiated coverage on HilleVax (NASDAQ:HLVX) with a Buy rating and set a price target of $28.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:25 am

HARP

HC Wainwright & Co. analyst Swayampakula Ramakanth has maintained a Buy rating on Harpoon Therapeutics (NASDAQ:HARP) and increased the price target from $7.5 to $12.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:18 am

DRD

HC Wainwright & Co. analyst Heiko Ihle has maintained a Buy rating on DRDGold (NYSE:DRD) but has reduced the price target from $17 to $13.25.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:16 am

TWLO

Needham analyst Ryan Koontz has maintained a Buy rating on Twilio (NYSE:TWLO) and increased the price target from $70 to $80.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:14 am

MSCI

Morgan Stanley analyst Toni Kaplan has upgraded MSCI Inc. (NYSE:MSCI) from Equal-Weight to Overweight and increased the price target from $526 to $600.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:12 am

KBH

Barclays analyst Matthew Bouley has maintained an Overweight rating on KB Home (NYSE:KBH) and increased the price target from $57 to $68.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:12 am

HCAT

JP Morgan analyst Anne Samuel has upgraded Health Catalyst (HCAT) from Neutral to Overweight while reducing the price target from $14 to $11.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:10 am

MHK

Barclays analyst Matthew Bouley upgraded Mohawk Industries (NYSE:MHK) from Underweight to Equal-Weight and increased the price target from $80 to $100.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:06 am

JELD

Barclays analyst Matthew Bouley has maintained an Equal-Weight rating on JELD-WEN Holding (NYSE:JELD) and increased the price target from $16 to $18.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:04 am

FBIN

Barclays analyst Matthew Bouley has maintained an Overweight rating on Fortune Brands (NYSE:FBIN) and increased the price target from $66 to $87, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 13, 2023 | 11:03 am